White Blood Cell News and Research

RSS

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes - which play a central role in the body's immune response - with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA).

26 Nov 2013

Staphylococcus Aureus Bacteria anticipates and turns immune defenses against the host

Around 20 percent of all humans are persistently colonized with Staphylococcus aureus bacteria, a leading cause of skin infections and one of the major sources of hospital-acquired infections, including the antibiotic-resistant strain MRSA.

20 Nov 2013

GM-CSF therapy does not improve treadmill walking time in patients with peripheral artery disease

Joseph Poole, M.D., Ph.D., of the Emory University School of Medicine, Atlanta, and colleagues studied whether therapy with granulocyte-macrophage colony stimulating factor (GM-CSF), an agent that functions as a white blood cell growth factor, would improve walking performance in patients with symptomatic peripheral artery disease (a form of vascular disease in which there is partial or total blockage of an artery, usually one leading to a leg or arm).

19 Nov 2013

Study: Blood cell growth factor improves effects of exercise in patients with peripheral artery disease

A blood cell growth factor can boost the effects of exercise in improving mobility for patients with peripheral artery disease, a clinical study has shown.

19 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Scientists discover new drug mechanism to reduce risk of infections

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection.

15 Nov 2013

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics biotechnologies GmbH and Roche today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.

13 Nov 2013

HIV infection, not antiretroviral therapy associated with risk for atherosclerosis

HIV infection, not antiretroviral therapy (ART), is associated with risk for atherosclerosis in patients with no history of smoking, particularly those infected for eight years or more.

31 Oct 2013

Researchers find more accurate method to screen for meningococcal infection

Researchers from the University of Missouri School of Medicine have found a more accurate method to screen for bacterial meningococcal infection in its early stages, when it's hardest to detect. According to the researchers, the method for diagnosis could save lives by getting patients treatment earlier, when the infection is most treatable.

31 Oct 2013

Janssen submits Marketing Authorization Application for Ibrutinib

Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.

30 Oct 2013

Researchers discover potential method to identify TBI using positron PET scans

Accurately diagnosing traumatic brain injuries (TBI) and concussions is difficult, as standard CT or MRI scans can't see most changes to the brain caused by these injuries.

24 Oct 2013

Amgen Buys Roche Rights To Neutropenia Drugs

...

22 Oct 2013

Research findings point the way to new class of antibiotics for skin and heart infections

Researchers at NYU Langone Medical Center have discovered a new mechanism by which the deadly Staphylococcus aureus bacteria attack and kill off immune cells. Their findings, published today in the journal Cell Host & Microbe, explain a critical survival tactic of a pathogen that causes more skin and heart infections than any other microbe, and kills more than 100,000 Americans every year.

17 Oct 2013

Research shows inhibition of Rcan1 protein may reduce atherosclerosis in mice

Researchers of the Spanish research council (Consejo Superior de Investigaciones Cient-ficas, CSIC) and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that inhibiting the protein Rcan1 in mice reduces the burden of atherosclerosis, one of the commonest cardiovascular diseases.

16 Oct 2013

Researchers made breakthrough development in inhibitory therapeutic for hypersensitive allergic reactions

New research published in the journal Nature Chemical Biology shows that a group of scientists, led by faculty at the University of Notre Dame, has made concrete progress toward the development of the first-ever inhibitory therapeutic for Type I hypersensitive allergic reactions.

10 Oct 2013

Research: Children with inherited anti-inflammatory defect may have predisposition to lymphoma

New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, the Journal of the American Society of Hematology (ASH), reveal an important association between the genetic defect, which causes chronic intestinal inflammation and early onset inflammatory bowel disease, and its role in cancer development in infants and children.

3 Oct 2013

Mutant protein blocks HIV infection and transmission, scientists find

A mutant of an immune cell protein called ADAP (adhesion and degranulation-promoting adaptor protein) is able to block infection by HIV-1 (human immunodeficiency virus 1), new University of Cambridge research reveals. The researchers, who were funded by the Wellcome Trust, believe that their discovery will lead to new ways of combatting HIV.

2 Oct 2013

FDA grants accelerated approval of Perjeta for people with HER2-positive early stage breast cancer

The U.S. Food and Drug Administration granted accelerated approval of a Perjeta- (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.